LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the “Company” or “Lightlake”), an early stage biopharmaceutical company using its expertise of opioid antagonists to develop modern treatments for addictions and related disorders, announced today its financial results for the year ended June 30, 2011.
